What is the maximum recommended dose of naltrexone (opioid receptor antagonist) for a patient with opioid or alcohol dependence?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maximum Dose of Naltrexone

The maximum recommended dose of naltrexone is 50 mg daily for oral formulations in the treatment of opioid or alcohol dependence, or 380 mg monthly for the extended-release injectable formulation (Vivitrol). 1

Standard Dosing for Alcohol Dependence

  • The FDA-approved dose for alcohol dependence is 50 mg once daily, which was the regimen used in placebo-controlled trials demonstrating efficacy for up to 12 weeks. 1
  • For the naltrexone/bupropion combination product (Contrave) used in obesity management, the maximum dose is two 8 mg/90 mg tablets twice daily, providing a total daily naltrexone dose of 32 mg. 2
  • The 50 mg daily dose has been shown to reduce relapse rates by approximately 50% compared to placebo when combined with behavioral treatment. 3

Standard Dosing for Opioid Dependence

  • Treatment should be initiated with 25 mg of naltrexone on day one, and if no withdrawal signs occur, the dose may be increased to 50 mg daily thereafter. 1
  • A dose of 50 mg once daily produces adequate clinical blockade of parenterally administered opioids. 1
  • Patients must be opioid-free for a minimum of 7-10 days for short-acting opioids before initiating naltrexone to avoid precipitated withdrawal. 1

Extended-Release Injectable Formulation

  • Injectable naltrexone (Vivitrol) is administered as 380 mg intramuscularly once every 28 days for both alcohol and opioid dependence. 4
  • The injectable formulation was designed to improve adherence by eliminating the need for daily dosing and maintains therapeutic naltrexone levels throughout the 1-month treatment cycle. 5
  • For surgical procedures, extended-release naltrexone should be held for 24-30 days after the last injection if opioids are expected perioperatively. 6, 4

Alternative Dosing Schedules

  • While 50 mg daily is standard, alternative regimens include 100 mg on Mondays and Wednesdays, and 150 mg on Fridays for supervised administration settings. 1
  • These flexible dosing schedules may be employed when supervised administration is necessary but do not exceed the weekly equivalent of 350 mg. 1

Low-Dose and Ultra-Low-Dose Naltrexone

  • Low-dose naltrexone (LDN) refers to doses of 1-5 mg daily, which is used off-label for various conditions and operates through different pharmacodynamic mechanisms than standard doses. 4, 7
  • Ultra-low-dose naltrexone (ULDN) at less than 1 μg per day has been used to potentiate opioid analgesia but is not relevant to addiction treatment dosing. 7

Safety Considerations at Maximum Dose

  • Hepatotoxicity is a concern only at supratherapeutic doses much higher than the standard 50 mg daily dose; at 50 mg/day, naltrexone does not appear to be hepatotoxic. 8, 3
  • Liver function tests should be monitored at baseline and every 3-6 months during treatment. 4
  • The most common adverse effects at 50 mg daily include nausea, vomiting, and headache, which are generally mild to moderate. 3, 5

Critical Warnings About Exceeding Maximum Dose

  • Do not exceed 50 mg daily for oral naltrexone or 380 mg monthly for injectable formulations, as higher doses increase the risk of hepatotoxicity without additional therapeutic benefit. 1, 8
  • Patients who discontinue naltrexone have increased risk of opioid overdose and death due to decreased opioid tolerance, regardless of the dose used. 4
  • Naltrexone cannot be used in patients requiring opioids for pain control as it blocks pain relief from opioid agonists at all therapeutic doses. 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Naltrexone Treatment for Opioid and Alcohol Dependence

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Ultra-Low-Dose Naltrexone Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.

Medical sciences (Basel, Switzerland), 2018

Research

Naltrexone in alcohol dependence.

American family physician, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.